Founded in 1995 by Dr Philippe Genne, the Company's CEO and Chairman, Oncodesign is a biopharma company dedicated to the precision medicine. With its unique experience acquired by working with more than 600 clients, including the world's largest pharmaceutical companies, along with its comprehensive technological platform combining state-of-the-art medicinal chemistry, pharmacology, regulated bioanalysis and medical imaging, Oncodesign is able to predict and identify, at a very early stage, each molecule's therapeutic usefulness and potential to become an effective drug. Applied to kinase inhibitors, which represent a market estimated at over $46 billion in 2016 and accounting for almost 25% of the pharmaceutical industry's R&D expenditure, Oncodesign's technology has already enabled the targeting of several promising molecules with substantial therapeutic potential, in oncology and elsewhere, along with partnerships with pharmaceutical groups such as Bristol-Myers Squibb and UCB. Oncodesign is based in Dijon, France, in the heart of the town's university and hospital hub, and within the Paris-Saclay cluster, Oncodesign has 215 employees and subsidiaries in Canada and the USA.

Kinase inhibitor Drug & Biomarker Discovery Novel inflammatory target based drug discovery Oncology advanced in vitro and in vivo pharmacology Immunomodulation in oncology DMPK/ADME Medicinal chemistry Bioanalysis Translational Biomarkers Biobanking Biodecontamination/Biosafety Kinase inhibitor Drug & Biomarker Discovery medicinal chemistry drug discovery drug analysis Biopharma Licencing Partnering vivo vitro models inflammatory diseases infectious diseases Kinase inhibitor Drug & Biomarker Discovery